MARK2 and thyroid gland carcinoma: Next-generation IHC using molecular markers such as B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E, rat sarcoma viral oncogene homolog (RAS) Q61R, pan-tropomyosin receptor kinase (pan-TRK), anaplastic lymphoma kinase (ALK), phosphatase and tensin homolog (PTEN), and beta-catenin shows great promise for the diagnosis and molecular classification of thyroid carcinomas [37].